Posted by Michael Wonder on 26 Jan 2022
PHARMAC confirms access criteria for COVID-19 treatments
26 January 2022 - PHARMAC has today confirmed the access criteria for two COVID-19 treatments – baricitinib and casirivimab with imdevimab (branded as Ronapreve).
Both will be available for use in DHB hospitals from 1 February 2022.
